10x Genomics, Inc. (TXG) FY2025 10-K Annual Report
10x Genomics, Inc. (TXG) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 13, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
10x Genomics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: integrated life sciences technology products and software for analyzing biological systems with high resolution and scale
- • New acquisition in 2025: Scale Biosciences, adding QuantumScale single cell RNA and methylation kits to single cell portfolio
- • Strategic emphasis on expanding spatial portfolio with Visium CytAssist instrument and new Xenium analyzer for in situ RNA analysis
- • Employee count increased to 1,178 in 2025, including 332 in R&D and 473 in sales/marketing/support
- • Noteworthy: Sold 1,007 instruments and 424,000 consumable reactions in 2025, reflecting growth in consumable reactions despite slight instrument sales decline vs 2024
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided text
- • No segment performance data included
- • Cash flow, buybacks, dividends, and capex data not included
- • Forward-looking statements caution on risks and uncertainties without specific guidance
Risk Factors
- • Regulatory/legal risk: Patent litigation settlements with Vizgen (Feb 2025, $26M upfront) and Bruker (May 2025, $68M installments) impacting license and royalty revenue
- • Geopolitical/macroeconomic risk: Foreign currency fluctuations affecting revenue, mainly in euro, GBP, and JPY markets, causing realized/unrealized gains/losses of $4.6M in 2025
- • Operational/supply chain risk: $7.8M increase in inventory write-downs due to product mix changes and manufacturing cost pressures in 2025
- • Competitive/market disruption risk: Price declines of Spatial instruments caused 39% revenue drop ($35.9M) in 2025 amid competition and market pricing pressure
- • Financial/structural risk: Dependence on contingent consideration of up to $30M from Scale Bio acquisition, with fair value remeasured quarterly causing revenue and income fluctuation
10x Genomics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$643M
▲ +5.2% YoY
Net Income
-$44M
▲ +76.2% YoY
Gross Margin
69.1%
▲ +119bp YoY
Operating Margin
-9.5%
▲ +2237bp YoY
Net Margin
-6.8%
▲ +2313bp YoY
ROE
-5.5%
▲ +2025bp YoY
Total Assets
$1.0B
▲ +13.4% YoY
EPS (Diluted)
$-0.35
▲ +77.0% YoY
Operating Cash Flow
$136M
▲ +1941.6% YoY
Source: XBRL data from 10x Genomics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on 10x Genomics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.